摘要
目的 综合评价阿苯达唑脂质体 (L -ABZ)治疗人体包虫病的疗效 ,并进行安全性考察 ,为该药在临床的应用提供客观依据。方法 临床治疗了 66例包虫病患者 ,其中囊型包虫病 5 6例、泡型包虫病 10例 ,口服阿苯达唑脂质体 10mg·kg-1 ·d-1 ,一天两次 ,连续服用 ,疗程 3～ 12个月 ,通过影像学指标观察 ,结合临床症状和体征及生化指标进行综合评价 ,动态随访 3～ 2 4个月。按治愈率、有效率、部分有效率、无效率以及总有效率判断疗效 ,并对单囊型及与多子囊型以及原发、复发病人进行对照分析。结果 共治愈 2 0例 ( 2 0 /66) ,治愈率为 3 0 . 3 %;有效 2 9例 ( 2 9/66) ,有效率 43 . 9%;部分有效 10例 ( 10 /66) ,部分有效率 15 . 1%;无效 7例 ( 7/66) ,无效率 10 . 6%;总有效率为 89. 3 %( 5 9/66)。其中 ,单囊型的治愈率明显高于多子囊型 ,但二者的有效率无显著性差异 (P <0 . 1) ;而原发、复发病人的治疗阿苯达唑脂质体的疗效无明显差异 (P >0 . 1) ;泡型包虫病患者 ,约 5 0 %病例临床疗效明显。在安全性观察中 ,主观症状阳性率为 13 . 6%( 9/66) ,生化指标阳性率为 12 . 1%( 8/66)。结论 阿苯达唑脂质体口服液是目前有效的一种抗包虫病新药剂型 ,具有疗效较高 ,低毒、副作用小。
Objective\ To assess the therapeutic efficacy on liposomal Albendazole on human echinococcosis so as to provide more evidence and theoretical basis for further clinical application. Methods\ In a total of 66 patients with CE and AE, 56 cases with CE and 10 cases with AE were orally taken L-ABZ with dosage of 10mg·kg -1 ·d -1 ,twice daily for 3～12 months. Therapeutic effect and reliability for L-ABZ have been evaluated by images(US,CT,MRI), clinical symptoms, labortory tests and followed up routinely from 3 to 24 months. The common therapeutic standards were classified as cure, effectiveness, partial effectiveness and noneffectiveness. Effects of L-ABZ were analyzed for the types of simple cyst and multiple daughter cyst. At the same time, positive rate about subjective symptoms and labortory tests were regarded as standard of side-effects of L-ABZ. Result\ In total of 66 patients,20 cases(30.3%) were cured, 29 cases(43.9%) as effective, 10 cases(15.1%) as partial effective, 7 cases (10.6%) as ineffective. The total effective rate was 89.3%. By analyzing, the effects of L-ABZ for type of simple cyst (CE 1) is more sensitive than type of multiple daughter cyst (CE 2) in rate of cure, however, there were no difference between CE 1 and CE 2 by comparison of the total effective rate. In AE patients, over half were better treated. In observation of side-effects, positive rate about subjective symptoms and laboratory tests were respectively 13.6%(9/66)and 12.1% (8/66). Conclusion\ L ABZ can be considered as a new furmulation with better effect for the treatment of human echinococcosis and slight side effects.
出处
《地方病通报》
2004年第1期16-19,F004,共5页
Endemic Diseases Bulletin
基金
国家自然科学基金 (39860 0 78)
英国威尔卡姆基金项目资助
关键词
包虫病
阿苯达唑
脂质体
药物治疗学
疗效观察
Echinococcosis
Therapeutic observation
Liposomes
Albendazole
Pharmacotherapeutics
